AI Terminal
DIACEUTICS PLC
Earnings Release • Jul 26, 2022
7596_rns_2022-07-26_cbdfa152-7a68-42fd-a07f-2d2fb7ca8498.html
Earnings Release
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information 
RNS Number : 6811T
Diaceutics PLC
26 July 2022
26 July 2022
Diaceutics PLC
("Diaceutics" or "the Company")
Trading update for the six months ended 30 June 2022
Notice of Results
Strong market momentum and DXRX platform adoption provides increased revenue visibility
Diaceutics PLC, (AIM: DXRX), a leading diagnostic commercialisation company which provides data, analytics and technology enabled services via its proprietary DXRX platform to the precision medicine market, announces the following unaudited trading update for the six months ended 30 June 2022.
The Company has enjoyed a positive start to the year, delivering H1 revenue and order book1 growth in line with the Board's expectations.
Revenue growth was approximately 25% to £7.5 million (H1 2021: £6.0 million, 18% on a constant currency basis) with more than 75% of revenues generated through the Company's DXRX platform, up from 60% for the year ended 31 December 2021.
The DXRX platform-enabled products and services have continued to increase revenue quality and visibility and have resulted in a meaningful future multi-year order book for the first time. Diaceutics grew the order book at 30 June 2022 to around £10 million, up from £1.7 million at 31 December 2021, with around 37% of the order book expected to be realised in H2 2022 and the remaining in 2023 and beyond.
Cash and cash equivalents increased to £20.4 million (31 December 2021: £19.7 million) and the Company continues to be debt free.
Notice of Results
The Company intends to report unaudited results for the six months ended 30 June 2022 on 27 September 2022.
Peter Keeling, CEO and Founder of Diaceutics commented:
"I am pleased to report a positive start to 2022, with revenue and order book growth in line with expectations. We are also seeing normal market conditions beginning to resume, and our continuing investment in our platform business model is allowing us to take advantage of the growing market opportunity and better assist our Pharma customers' shift towards precision medicine and technology enabled commercialisation.
We remain confident in our strategy and in our ability to secure future growth as we continue to hit our key milestones for platform network expansion and the introduction of innovative new products."
1 Order book is the value of future contracted revenue not yet recognised
Enquiries:
| Diaceutics PLC | |
| Nick Roberts, Chief Financial Officer | Via Alma PR |
| Stifel Nicolaus Europe Limited (Nomad & Broker) | Tel: +44 (0)20 7710 7600 |
| Ben Maddison | |
| Stewart Wallace | |
| Nick Adams | |
| Alma PR | Tel: +44(0)20 3405 0205 |
| Caroline Forde | [email protected] |
| Kieran Breheny | |
| Matthew Young |
About Diaceutics
At Diaceutics we believe that every patient should have access to the right treatment at the right time. We provide the world's leading pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics enabled by DXRX - The Diagnostic Network®.
DXRX is the world's first diagnostic commercialisation platform for precision medicine, integrating multiple pipelines of real-world diagnostic testing data from a global network of laboratories.
Diaceutics' data capability is one of the three key value drivers it has integrated into its unique DXRX platform alongside its global Lab network and product suite tailored for Precision testing.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
TSTRAMRTMTITBLT